Logo image of ALLO

ALLOGENE THERAPEUTICS INC (ALLO) Stock Fundamental Analysis

USA - NASDAQ:ALLO - US0197701065 - Common Stock

1.155 USD
0 (-0.43%)
Last: 9/22/2025, 1:32:03 PM
Fundamental Rating

3

Overall ALLO gets a fundamental rating of 3 out of 10. We evaluated ALLO against 538 industry peers in the Biotechnology industry. The financial health of ALLO is average, but there are quite some concerns on its profitability. ALLO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALLO has reported negative net income.
ALLO had a negative operating cash flow in the past year.
In the past 5 years ALLO always reported negative net income.
ALLO had a negative operating cash flow in each of the past 5 years.
ALLO Yearly Net Income VS EBIT VS OCF VS FCFALLO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -50.34%, ALLO perfoms like the industry average, outperforming 49.81% of the companies in the same industry.
With a Return On Equity value of -68.76%, ALLO perfoms like the industry average, outperforming 56.69% of the companies in the same industry.
Industry RankSector Rank
ROA -50.34%
ROE -68.76%
ROIC N/A
ROA(3y)-46.19%
ROA(5y)-36.74%
ROE(3y)-58.29%
ROE(5y)-45.22%
ROIC(3y)N/A
ROIC(5y)N/A
ALLO Yearly ROA, ROE, ROICALLO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALLO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALLO Yearly Profit, Operating, Gross MarginsALLO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200K -400K -600K -800K -1M

More info and screens

6

2. Health

2.1 Basic Checks

ALLO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALLO has been increased compared to 1 year ago.
The number of shares outstanding for ALLO has been increased compared to 5 years ago.
There is no outstanding debt for ALLO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALLO Yearly Shares OutstandingALLO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
ALLO Yearly Total Debt VS Total AssetsALLO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ALLO has an Altman-Z score of -5.57. This is a bad value and indicates that ALLO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ALLO (-5.57) is worse than 62.45% of its industry peers.
There is no outstanding debt for ALLO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.57
ROIC/WACCN/A
WACC9.84%
ALLO Yearly LT Debt VS Equity VS FCFALLO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 8.92 indicates that ALLO has no problem at all paying its short term obligations.
With a decent Current ratio value of 8.92, ALLO is doing good in the industry, outperforming 77.32% of the companies in the same industry.
ALLO has a Quick Ratio of 8.92. This indicates that ALLO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ALLO (8.92) is better than 77.51% of its industry peers.
Industry RankSector Rank
Current Ratio 8.92
Quick Ratio 8.92
ALLO Yearly Current Assets VS Current LiabilitesALLO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 27.45% over the past year.
ALLO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
ALLO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -91.70% yearly.
EPS 1Y (TTM)27.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.29%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-91.7%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ALLO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.96% yearly.
Based on estimates for the next years, ALLO will show a very strong growth in Revenue. The Revenue will grow by 475.94% on average per year.
EPS Next Y24.04%
EPS Next 2Y13.69%
EPS Next 3Y7.04%
EPS Next 5Y17.96%
Revenue Next Year-83.3%
Revenue Next 2Y-42.21%
Revenue Next 3Y681.22%
Revenue Next 5Y475.94%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALLO Yearly Revenue VS EstimatesALLO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ALLO Yearly EPS VS EstimatesALLO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALLO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALLO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALLO Price Earnings VS Forward Price EarningsALLO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALLO Per share dataALLO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.69%
EPS Next 3Y7.04%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALLO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALLOGENE THERAPEUTICS INC

NASDAQ:ALLO (9/22/2025, 1:32:03 PM)

1.155

0 (-0.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners67.45%
Inst Owner Change-8.47%
Ins Owners7.04%
Ins Owner Change-0.08%
Market Cap256.27M
Analysts83
Price Target7.71 (567.53%)
Short Float %13.1%
Short Ratio4.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.41%
Min EPS beat(2)5.26%
Max EPS beat(2)17.55%
EPS beat(4)4
Avg EPS beat(4)11.3%
Min EPS beat(4)4.75%
Max EPS beat(4)17.64%
EPS beat(8)8
Avg EPS beat(8)11.46%
EPS beat(12)11
Avg EPS beat(12)9.55%
EPS beat(16)15
Avg EPS beat(16)9.2%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)2
Avg Revenue beat(8)-18.94%
Revenue beat(12)5
Avg Revenue beat(12)47.5%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.45%
PT rev (3m)-7.8%
EPS NQ rev (1m)3.1%
EPS NQ rev (3m)11.02%
EPS NY rev (1m)0%
EPS NY rev (3m)5.7%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-9.99%
Revenue NY rev (3m)83.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 0.74
EV/EBITDA N/A
EPS(TTM)-1.11
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0
BVpS1.55
TBVpS1.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -50.34%
ROE -68.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.19%
ROA(5y)-36.74%
ROE(3y)-58.29%
ROE(5y)-45.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.56%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.92
Quick Ratio 8.92
Altman-Z -5.57
F-Score3
WACC9.84%
ROIC/WACCN/A
Cap/Depr(3y)17.35%
Cap/Depr(5y)225.27%
Cap/Sales(3y)2304.28%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.29%
EPS Next Y24.04%
EPS Next 2Y13.69%
EPS Next 3Y7.04%
EPS Next 5Y17.96%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-91.7%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-83.3%
Revenue Next 2Y-42.21%
Revenue Next 3Y681.22%
Revenue Next 5Y475.94%
EBIT growth 1Y53.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.47%
EBIT Next 3Y-0.97%
EBIT Next 5Y4.47%
FCF growth 1Y28.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.48%
OCF growth 3YN/A
OCF growth 5YN/A